Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia

Physiology and Behavior

Volumn 152, Issue , 2015, Pages 182-193

  Jain, Swati ^a,c   Sharma, Bhupesh ^a,b  

^a BHARAT INSTITUTE OF TECHNOLOGY   (India)

^b Dilshad Garden   (India)

^c AMITY UNIVERSITY   (India)

Author keywords

Attentional set shifting; Blood brain barrier; DPP 4 inhibitor; Morris water maze; Oxidative stress

Indexed keywords

BRAIN PROTEIN; CALCIUM; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; GLUTATHIONE; NITRATE; NITRITE; PIOGLITAZONE; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NEUROPROTECTIVE AGENT; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN CORTEX; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; INFLAMMATION; LATENT PERIOD; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PANCREAS RESECTION; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ATTENTION; BRAIN; CAPILLARY PERMEABILITY; DEMENTIA, VASCULAR; DISEASE MODEL; DRUG EFFECTS; EXECUTIVE FUNCTION; MAZE TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ADAMANTANE; ANIMALS; ATTENTION; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; DEMENTIA, VASCULAR; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; EXECUTIVE FUNCTION; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; NITRILES; PANCREATECTOMY; PYRROLIDINES; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84943572590     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.09.007     Document Type: Article

References (61)

1. Allaman-Pillet N., Størling J., Oberson A., Roduit R., Negri S., Sauser C., Nicod P., Beckmann J.S., Schorderet D.F., Mandrup-Poulsen T., Bonny C. Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1. J. Biol. Chem. 2003, 278:48720-48726.
2. Almasi-Nasrabadi M., Javadi-Paydar M., Mahdavian S., Babaei R., Sharifian M., Norouzi A., Dehpour A.R. Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Behav. Brain Res. 2012, 231:138-145.
3. Amber C.F., Zeynep T.K., Evren O., Yusuf B., Can A.K., Belma T. Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation. Mol. Biol. Rep. 2014, 41:4853-4863.
4. Ananthi J., Prakasam A., Pugalendi K.V. Antihyperglycemic activity of Eclipta Alba leaf on alloxan-induced diabetic rats. Yale J. Biol. Med. 2003, 76:97-102.
5. Bao W., Morimoto K., Hasegawa T., Sasaki N., Yamashita T., Hirata K., Okita Y., Okada K. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J. Vasc. Surg. 2014, 59:1098-1108. 10.1016/j.jvs.2013.04.048.
6. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 2000, 20:4320-4324.
7. Ceriello A., Quagliaro L., D'Amico M., Di Filippo C., Marfella R., Nappo F., Berrino L., Rossi F., Giugliano D. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002, 51:1076-1082.
8. Soto C., Raya L., Pérez J., González I., Pérez S. Silymarin induces expression of pancreatic Nkx6.1 transcription factor and β-cells neogenesis in a pancreatectomy model. Molecules 2014, 19:4654-4668.
9. Gale J.E., Cox H.I., Qian J., Block G.D., Colwell C.S., Matveyenko A.V. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J. Biol. Rhythm. 2011, 26:423-433. 10.1177/0748730411416341.
10. Gardoni F., Kamal A., Bellone C., Biessels G.J., Ramakers G.M., Cattabeni F., Gispent W.H., Di Luca M. Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. J. Neurochem. 2002, 80(3):438-447.
11. Gault V.A., Lennox R., Flatt P.R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes. Metab. 2015, 10.1111/dom.12432.
12. Gupta A.K., Verma A.K., Kailashiya J., Singh S.K., Kumar N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 2012, 23:565-570.
13. Gupta S., Sharma B. Pharmacological modulation of I (1)-imidazoline and α2-adrenoceptors in sub-acute brain ischemia induced vascular dementia. Eur. J. Pharmacol. 2014, 723:80-90.
14. Gupta S., Sharma B. Pharmacological benefit of I (1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain Res. Bull. 2014, 102:57-68.
15. Gupta S., Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease. Behav. Pharmacol. 2014, 732:111-122.
16. He Z., Zhang X., Chen C., Wen Z., Hoopes S.L., Zeldin D.C., Wang D.W. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodeling induced by angiotensin II. Cardiovasc. Res. 2015, 105(3):304-317.
17. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 2011, 27:547-558.
18. Huang W., Eum S.Y., András I.E., Hennig B., Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J. 2009, 23:1596-1606. 10.1096/fj.08-121624.
19. Inestrosa N.C., Godoy J.A., Quintanilla R.A., Koenig C.S., Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 2004, 304:91-104.
20. Ishibashi Y., Matsui T., Maeda S., Higashimoto Y., Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 2013, 12:125.
21. Jing L., Wang J.G., Zhang J.Z., Cao C.X., Chang Y., Dong J.D., Guo F.Y., Li P.A. Upregulation of ICAM-1 in diabetic rats after transient forebrain ischemia and reperfusion injury. J. Inflamm. (Lond) 2014, 11(1):35. 10.1186/s12950-014-0035-2.
22. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
23. Kaundal R.K., Sharma S.S. Ameliorative effects of GW1929, a nonthiazolidinedione pparγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. Curr. Neurovasc. Res. 2011, 8(3):236-245.
24. Kaur B., Singh N., Jaggi A.S. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam. Clin. Pharmacol. 2009, 23:557-566.
25. Ketsawatsomkron P., Sigmund C.D. Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. Curr. Opin. Nephrol. Hypertens. 2015, 24(2):123-130.
26. Kobata A., Kotani T., Komatsu Y., Amagase K., Kato S., Takeuchi K. Dual action of nitric oxide in the pathogenesis of ischemia/reperfusion-induced mucosal injury in mouse stomach. Digestion 2007, 75:188-197.
27. Kosaraju J., Murthy V., Khatwal R.B., Dubala A., Chinni S., Muthureddy Nataraj S.K., Basavan D. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol. 2013, 65(12):1773-1784.
28. Lee B.H., Hsu W.H., Chang Y.Y., Kuo H.F., Hsu Y.W., Pan T.M. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo. Free Radic. Biol. Med. 2012, 53(11):2008-2016.
29. Li R., Zhang H., Wang W., Wang X., Huang Y., Huang C., Gao F. Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOSsignaling. Eur. J. Pharmacol. 2009, 628:140-147.
30. Li Y., Xiao J., Tian H., Pei Y., Lu Y., Han X., Liu Y., Zhong W., Sun B., Fang F., Shu H. The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice. Peptides 2013, 49:91-99.
31. Lim S., Choi S.H., Shin H. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012, 7.
32. Madeo J., Frieri M. Alzheimer's disease and immunotherapy. Aging Dis. 2013, 4(4):210-220.
33. Manaenko A., Chen H., Kammer J., Zhang J.H., Tang J. Comparison Evans blue injection routes: intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model. J. Neurosci. Methods 2011, 195(2):206-210.
34. Maurya S.K., Mishra J., Tripathi V.K., Sharma R., Siddiqui M.H. Cypermethrin induces astrocyte damage: role of aberrant Ca(2+), ROS, JNK, P38,matrix metalloproteinase 2 and migration related reelin protein. Pestic. Biochem. Physiol. 2014, 111:51-59. (Epub 2014 Apr 12). 10.1016/j.pestbp.2014.03.005.
35. Neumeier M., Weigert J., Buettner R., Wanninger J., Schäffler A., Müller A.M., Killian S., Sauerbruch S., Schlachetzki F., Steinbrecher A., Aslanidis C., Schölmerich J., Buechler C. Detection of adiponectin in cerebrospinal fluid in humans. Am. J. Physiol. Endocrinol. Metab. 2007, 293(4):E965-E969.
36. 2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J. Neurochem. 2009, 109(6):1800-1811. 10.1111/j.1471-4159.2009.06107.x.
37. Pintana H., Apaijai N., Chattipakorn N., Chattipakorn S.C. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 2013, 218(1):1-11. 10.1530/JOE-12-0521.
38. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator activated receptor gamma-dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1810-1816.
39. Rani A.J., Mythili S.V. Study on total antioxidant status in relation to oxidative stress in type 2 diabetes mellitus. J. Clin. Diagn. Res. 2014, 8(3):108-110. 10.7860/JCDR/2014/7603.4121.
40. Sain H., Sharma B., Jaggi A.S., Singh N. Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats. Neuroscience 2011, 192:322-333.
41. Sakr H.F. Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J. Physiol. Pharmacol. 2003, 64(5):613-623.
42. Sarafidis P.A., Lasaridis A.N. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am. J. Hypertens. 2006, 19(6):646-653.
43. Sharma B., Singh N. Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA-salt hypertension-induced vascular dementia in rats. Psychopharmacology 2012, 223(3):307-317.
44. Sharma B., Singh N. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol. Biochem. Behav. 2012, 102:101-108.
45. Sharma B., Singh N. Salutary effect of nfκb inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 38(2):207-215.
46. Sharma B., Singh N. Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacol. Biochem. Behav. 2011, 100(2):320-329.
47. Sharma B., Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology 2011, 215(4):677-687. 10.1007/s00213-011-2164-0.
48. Samaras K., Sachdev P.S. Diabetes and the elderly brain: sweet memories?. Ther. Adv. Endocrinol. Metab. 2012, 6:189-196. 10.1177/2042018812469645.
49. Shemyakin A., Kövamees O., Rafnsson A., Böhm F., Svenarud P., Settergren M., Jung C., Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 2012, 126(25):2943-2950. 10.1161/CIRCULATIONAHA.112.140335.
50. Shimizu F., Sano Y., Tominaga O., Maeda T., Abe M.A., Kanda T. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-β by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol. Aging 2013, 34(7):1902-1912. 10.1016/j.neurobiolaging.2013.01.012.
51. Sun X., Lin Y., Huang Q., Shi J., Qiu L., Kang M., Chen Y., Fang C., Ye T., Dong S. Di(2-ethylhexyl) phthalate-induced apoptosis in rat INS-1 cells is dependent on activation of endoplasmic reticulum stress and suppression of antioxidant protection. J. Cell. Mol. Med. 2014, 10.1111/jcmm.12409.
52. Sun D., Shen M., Li J., Li W., Zhang Y., Zhao L., Zhang Z., Yuan Y., Wang H., Cao F. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc. Diabetol. 2011, 10:4. 10.1186/1475-2840-10-4.
53. Taheri S., Gasparovic C., Huisa B.N., Adair J.C., Edmonds E., Prestopnik J., Grossetete M., Shah N.J., Wills J., Qualls C., Rosenberg G.A. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 2011, 42(8):2158-2163. 10.1161/STROKEAHA.110.611731.
54. Ulusoy G.K., Celik T., Kayir H., Gürsoy M., Isik A.T., Uzbay T.I. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res. Bull. 2011, 85:380-384.
55. van de Haar H.J., Burgmans S., Hofman P.A., Verhey F.R., Jansen J.F., Backes W.H. Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci. Biobehav. Rev. 2015, 49C:71-81. 10.1016/j.neubiorev.2014.11.022.
56. Wu Y.L., Ding Y.P., Gao J., Tanaka Y., Zhang W. Risk factors and primary prevention trials for type 1 diabetes. Int. J. Biol. Sci. 2013, 9(7):666-679. 10.7150/ijbs.6610.
57. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., Aronowski J. Neuronal ppargamma deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci. 2009, 29:6186-6195.
58. Zhu K.X., Nie S.P., Li C., Gong D., Xie M.Y. Ganoderma atrum polysaccharide improves aortic relaxation in diabetic rats via PI3K/Akt pathway. Carbohydr. Polym. 2014, 103:520-527. (Epub 2014 Jan 6). 10.1016/j.carbpol.2013.12.080.
59. Sharma B., Singh N. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr. Neurovasc. Res. 2010, 7(3):180-191.
60. Wang J., Zhang H.Y., Tang X.C. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol. Sin. 2009, 30(7):879-888.
61. Nassar N.N., Al-Shorbagy M.Y., Arab H.H., Abdallah D.M. Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 2015, 89:308-317.